



Atlas Genet Cytogenet Oncol Haematol. 2019; 23(7) 168 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS OPEN ACCESS JOURNAL 
BIRC5 (baculoviral IAP repeat containing 5) 
Paola Cristina Branco, Paula Christine Jimenez, João Agostinho Machado-Neto, Letícia 
Veras Costa-Lotufo 
Department of Pharmacology, Institute of Biomedical Sciences of the University of São Paulo, São 
Paulo, pbranco@usp.br (PCB); jamchadoneto@usp.br (JAM-N); costalotufo@usp.br (LVC-L) Brazil; 
Department of Marine Sciences, Federal University of Sao Paulo, Santos, paulacjimenez@gmail.com 
(PCJ), Brazil. 
Published in Atlas Database: January 2019 
Online updated version : http://AtlasGeneticsOncology.org/Genes/BIRC5ID797ch17q25.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/70468/01-2019-BIRC5ID797ch17q25.pdf 
DOI: 10.4267/2042/70468
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2019 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
BIRC5, also known as survivin, has been implicated 
in cell cycle progression and apoptosis avoidance. 
BIRC5 is highly expressed in embryonic tissues, 
however very low or absent in adult tissues. BIRC5 
overexpression has been frequently associated to 
cancer development, a poor prognosis and 
chemoresistance. Besides that, different BIRC5 
isoforms has been characterized and related to better 
or worse chemotherapy responses depending on the 
isoform and the cancer type. So far, many efforts 
have been conducted in order to deplete BIRC5 in 
cancer cells, including gene therapy, 
pharmacological and nanotechnological approaches. 
In this review, we will discuss the role of BIRC5 in 
cancer cell biology and its clinical significance, 
demonstrating its DNA/RNA and protein aspects, 
also its relevance for diagnosis and prognosis, and 
advances as a target for the treatment of different 
cancer types. 
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Identity 
Other names: API4, EPR-1 
HGNC (Hugo): BIRC5 
DNA/RNA 
Description 
The entire BIRC5 gene is approximately 11.4 Kb 
(start: 78214186 and end: 78225636 bp; orientation: 
Plus strand). 
Transcription 
There are three transcript variants deposited in the 
NCBI database 
(https://www.ncbi.nlm.nih.gov/gene).  
In general, they present three exons (exon 1, 2 and 3) 
that are responsible for encoding the BIR domain, 
which is conserved in all BIRC family members, and 
the exon 4 that is related to the coiled-coil (CC) 
domain.  
Variant 1 is the predominant transcript (cDNA: 2574 
bp), and encodes isoform 1 (142 amino acids [aa]).  
Variant 2 lacks an exon in the 3' coding region, 
which results in a frameshift (cDNA: 2537 bp) and, 
thus, in a changed protein (143 aa) with a different 
C-terminus from that of isoform 1 (isoform 2, also 
known survivin-ΔEx3). Variant 3 exhibits an 
alternate in-frame segment (cDNA: 2724 bp) and 
generates a longer (165 aa) and distinct protein 
(isoform 3, also known survivin-2B), compared to 
isoform 1.  
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Figure 1. BIRC5 structure and its splices variants. BIRC5 (also kwon as survivin) presents at least five variants with biological 
relevance for cancer. A. The protein structure of the most common variant observed presents 142 aa and is composed of a BIR 
domain that is responsible for its anti-apoptotic activity and a coiled coil. B. The BIRC5 pre mRNA of the most common 
expressed variant is composed of 3 exons that codifies the BIR domain and the exon 4 that codifies the coiled coil. This variant 
present anti-apoptotic activity. Survivin Ex3 has its exon 3 deleted and an insertion of a 3'UTR, this isoform codes a protein of 
143 aa and also exerts anti-apoptotic functions. Survivin-2B presents an insertion of an exon 2b located between exon 2 and 
exon 3, generates a protein of 165 aa with pro-apoptotic characteristics. Survivin-2α is characterized by the presence of exon 1 
and 2 and the insertion of a 3'UTR, this isoform codifies a protein of 74 aa with pro-apoptotic functions. Survivin-3B presents the 
insertion of exon 3 b between exon 3 and exon 4, which generates a protein of 165 aa with anti-apoptotic properties. Survivin-3α 
presents a deletion of exon 3 and generates a protein of 78 aa whose function remain controversial. Arrows indicate the stop 
codon. UTR- untranslated region. Red line indicates the BIR structure. 
 
Moreover, three additional transcript variants are 
reported in Ensembl (http://www.ensembl.org/): a 
transcript variant containing 568 bp, which generates 
a protein of 74 aa (also known as Survivin-2α); a 
transcript variant with 492 bp (cDNA) that produces 
a protein of 121 aa (also known as Survivin-3B); and 
a transcript variant comprised of 386 bp (cDNA) that 




The IAPs (Inhibitors of Apoptosis Proteins) are a 
family of proteins primarily known for inhibiting 
caspase activity, either directly or indirectly, thus 
preventing apoptotic cell death (Gyrd-Hansen and 
Meier, 2010). Still, the IAPs are further implicated 
in key roles in other processes, such as cell cycle, cell 
migration, inflammation and, even, in the innate 
immune response (de Almagro and Vucic, 2012).  
Structurally, members of the IAPs are characterized 
by the presence of at least one BIR (Baculovirus IAP 
repeat) domain, which contains nearly 80 amino acid 
residues and carries Zn2+ in the center. Such domain 
is a highly conserved sequence that mediates 
protein-protein interactions, an essential feature for 
their anti-apoptotic function. Within the eight human 
IAPs recognized ( NAIP [BIRC1], BIRC2 [cIAP1], 
BIRC3 [cIAP2], XIAP [BIRC4], survivin [BIRC5], 
BIRC6 [bruce], BIRC7 [livin] and BIRC8 [ILP-2]) 
there may be between one and three BIR domains, 
typically arranged in their N-terminal portion 
(Budhidarmo and Day, 2015; Lopez and Meier, 
2010).  
BIRC5 (survivin), the smallest among the IAPs (16.5 
kDa), was discovered in 1997 (Ambrosini et al., 
1997), is 142 amino acids (aa) long and has a single 
BIR domain (Peery et al., 2017). This protein is 
presented as a stable loop-shaped homodimer, 
formed by interactions of the N-terminal region 
through a predominantly hydrophobic interface 
(Chantalat et al., 2000; Verdecia et al., 2000). 
Furthermore, on the C-terminal portion, survivin 
carries an alpha-helix CC (coiled coil) domain, its 
unique structure (Chantalat et al., 2000; Coumar et 
al., 2013) which convenes the ability to associate to 
microtubules and a range of other proteins involved, 
mainly, in the process of mitosis, and further 
allowing for translocation among the different 
cellular compartments, such as mitochondria, 
cytoplasm and nucleus (Rodel et al., 2012) (Figure 
1).  
Since BIRC5 is connected to a diverse network of 
biochemical processes and therefore has remarkable 
multifunctionality, its modulation in cancer therapy 
continues to be extensively explored. Several 
survivin inhibitors have been identified by in vitro 
and in silico methods, such as antisense 
oligonucleotides, siRNA, dominant-negative 
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mutants, peptidomimetic molecules and other small 
inhibitory molecules, and even as anticancer vaccine 
(Fenstermaker et al., 2016; Sarvagalla et al., 2016). 
Expression 
BIRC5 is normally expressed in embryonic tissues 
and during fetal development, as well as in fast 
dividing normal cells (like bone marrow stem cells, 
basal epithelial cells and thymocytes, even if at lower 
concentrations), but is virtually undetectable in fully 
differentiated and healthy adult tissues (Adida et al., 
1998; Sah et al., 2006; Stauber et al., 2007). 
Throughout the cell cycle, BIRC5 is expressed only 
during mitosis, in a highly regulated manner 
comprising the chromosomal passenger complex 
(CPC), as it interacts with tubulin and kinetochores 
during metaphase, then participates in central 
spindle organization and cytokinesis, throughout 
anaphase (Szafer-Glusman et al., 2011).  
However, BIRC5 is expressed in cells that undergo 
malignant transformation, being overexpressed in 
numerous tumors (Altieri, 2001; LaCasse et al., 
2008). Recent studies evidenced that transcriptional 
activation is not the only cause for BIRC5 
overexpression, but also post-transcriptional 
regulation, specially coordinated by many 
alternative polyadenylation (APA) sites. For 
instance, in ovarian cancer, aberrant APA leads to 
shortening of the 3'-UTR region, enabling escape 
from negative regulation of miRNAs and causing 
up-regulation of BIRC5 (He et al., 2016).  
Clinically, overexpression of BIRC5 has been 
correlated with a poor prognosis of cancer, resistance 
to apoptosis induced by chemotherapy, decreased 
survival of patients and greater chances of relapse 
(Islam et al., 2000; Rodel et al., 2012). 
Localisation 
BIRC5 is located both in the cytoplasm and in the 
nucleus. Nuclear expression has been associated 
with a poor prognosis and chemoresistance (Du et 
al., 2015), which may differ among the different 
types of cancers (Shintani et al., 2013). BIRC5 splice 
variants were also related to subcellular localization. 
This has been shown in samples from acute myeloid 
leukemia patients, where wild-type survivin and the 
2B splice variant were expressed in the nucleus, 
cytoplasm or both, whereas the ΔEx3 isoform was 
only expressed in the nucleus (Serrano-Lopez et al., 
2013). However, considering pro-survival factors, 
localization is not the only relevant feature: it has 
been recently demonstrated that BIRC5 can be 
packaged into extracellular vesicles (endosomes) 
and its delivery may be guided by antiapoptosis 
stimuli from cancer cells and tumor 
microenvironment, inducing pro-survival 
competences in fibroblasts after treatment with 
paclitaxel. Conversely, knockdown of BIRC5 in 
those vesicles promoted increased cell sensitivity to 
chemotherapeutic agents (Kreger et al., 2016). 
Function 
Studies have shown that overexpression of BIRC5 
inhibits both the intrinsic and extrinsic pathways of 
apoptosis and the depletion of survivin in human cell 
culture impairs apoptosis and triggers cell division 
defects (Li et al., 1998; Roy et al., 2015). The 
antiapoptotic mechanism of BIRC5 still needs to be 
better clarified, however, both the direct or indirect 
binding of BIRC5 to caspases are proposed (Figure 
2) (Altieri, 2013; Garg et al., 2016; Li et al., 1998). 
Evidences also indicate that BIRC5 binds to XIAP, 
one of the best studied IAPs, forming a complex that 
protects XIAP against ubiquitination and 
proteosomal degradation.  
This complex then activates multiple signaling 
pathways, including NF-κB, inhibits caspases 
CASP3, CASP7 and CASP9, suppresses apoptosis 
and accelerates tumor progression. Other 
cytoprotective mechanisms have been proposed for 
BIRC5, including the ability of mitochondrial 
BIRC5 to sequester the pro-apoptotic DIABLO 
(Smac) protein from its binding to BIRC4 (also 
known as XIAP), or even preventing its release from 
mitochondria (Altieri, 2013; Coumar et al., 2013; 
Song et al., 2003). 
Interaction of BIRC5 with CDK4 has been 
associated with progression of the cell cycle. In 
mitosis, BIRC5 plays a key role in integrating the 
transient chromosome complex (CPC), along with 
INCENP, CDCA8 (borealin) and AURKB, which 
controls the formation and stabilization of the 
mitotic spindle (Altieri, 2013; Coumar et al., 2013). 
Activation of Wnt signaling induces β-catenin ( 
CTNNB1) and BIRC5 nuclear translocation, which 
contributes in mitotic spindle formation, further 
regulating CPC, β-catenin, STAT3 and HIF1A 
(Figure 2). BIRC5 also appears to be involved in the 
cellular response to stress through the interaction 
with various chaperones, such as AIP, HSPD1 
(HSP60) and HSP90AA1 (HSP90) (Altieri, 2013; 
Fortugno et al., 2003). Moreover, BIRC5 also 
partakes in the process of autophagy (Wang et al., 
2011) and in DNA repair among several tumor cell 
lines (Jiang et al., 2009). 
BIRC5 has also been shown to induce cell motility, 
metastasis and increased colonization capacity by 
AKT-mediated upregulation of the α5 integrin 
pathway in a melanoma model (McKenzie et al., 
2013).  
Additionally, BIRC5 plays an important role in 
angiogenesis, contributing to endothelial cell 
proliferation and migration, which was then linked 
to increased β-catenin protein levels that 
consequently promotes an elevated expression of 
BIRC5 and VEGF (Fernandez et al., 2014). 
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Figure 2. BIRC5: a multitask protein. BIRC5 (survivin) acts on cytoplasm and nucleus and is involved different cellular functions: 
cell survival, cell cycle progression, mitotic spindle formation and transcription activation. In cytoplasm, BIRC5 modulates 
apoptosis pathway by binding to and blocking initiator caspase 9 and effectors caspases 3 and 7, demonstrating to be involved in 
extrinsic and intrinsic apoptosis and contributing to cell survival. BIRC5 may be blocked by SMAC/DIABLO, a factor released by 
mitochondria. Also BIRC5 potentiates apoptosis inhibition through stabilization of BIRC4 (also kwon as XIAP). TGF-β signaling 
negatively regulates BIRC 5 by phosphorylating SMAD protein. p53-mediated signaling also downregulates BIRC5 functions. 
CDC phosphorylates BIRC5 and promotes its binding to CDK4 that may be translocated to nucleus, and thus promotes cell cycle 
progression. In nucleus, BIRC5 is involved in the mitotic spindle formation modulated by Wnt pathway through the 
phosphorylation inhibiton and nuclear translocation of β-catenin activating BIRC5 and associated to other proteins (not shown) 
form the Chromosomal Passenger Complex (CPC). The transcription activation of BIRC5 mRNA is mainly promoted by β-
catenin, STAT3 (signal transducer and activator of transcription-3) and HIF 1 α (hypoxia-inducible factor-1α). 
 
BIRC5 is also directly involved in enhancing anoikis 
resistance through miR-141/KLF12/Sp1/survivin 
axis. It is a consensus that anoikis resistance is 
crucial for establishing a metastatic niche and 
consequently promoting cancer progression and 
dissemination (Mak et al., 2017). Dissimilar 
functions have been attributed to the different 
isoforms of BIRC5. Survivin-2α and survivin-2B 
portray a proapoptotic activity profile, whereas 
Survivin-ΔEx3 and Survivin-3B show prominent 
antiapoptotic activity, with similar activities to those 
of survivin itself. These distinct variants can predict 
aggressiveness of cancer phenotype, thus 
contributing to prognosis (Caldas et al., 2005). 
BIRC5 can be released from tumor cells in exosomes 
(Khan et al., 2011). This information provided new 
insights into biomarkers for determination of early 
diagnosis and also to predict prognosis. In this 
context, the splice variant survivin-2B, in breast 
cancer, was shown to be expressed mostly in primary 
tumors and exclusively in early stage disease. 
Conversely, Survivin-ΔEx3 variant was most 
commonly expressed in late stages of breast cancer 
(Khan et al., 2014). Survivin-2B has been further 
reported to promote cell death in some cancer cells 
by promoting  
autophagy followed by cell death induced by 
accumulation and stabilization of IKBKB (IKKB) in 
the nucleus (Shi et al., 2014). 
Homology 
The BIRC5 gene is highly homologous among 
different species, as shown in Table 1, which 
demonstrates the comparison of variant 1 among 
different species.  
% Identity for: Homo 
sapiens BIRC5 
Symbol Protein DNA 
vs. P. troglodytes BIRC5 98.3 98.8 
vs. M. mulatta BIRC5 97.9 97.9 
vs. C. lupus BIRC5 90.8 90.1 
vs. B. taurus BIRC5 90.1 90.1 
vs. M. musculus Birc5 83.6 82.6 
vs. R. norvegicus Birc5 83.0 81.3 
vs. G. gallus BIRC5 60.6 65.7 
vs. X. tropicalis birc5.2 57.8 64.2 
vs. D. rerio Birc5a 54.3 58.0 
Table 1. Comparative identity of human BIRC5 with other 
species (Source: http://www.ncbi.nlm.nih.gov/homologene) 
 
 










Recurrent mutations in the BIRC5 gene are rare. 
Among the 47,119 unique samples reported in 
COSMIC (Catalogue of Somatic Mutations in 
Cancer; 
http://cancer.sanger.ac.uk/cancergenome/projects/c
osmic), only 43 presented BIRC5 mutations (29 
missense substitutions, 8 synonymous substitutions, 
3 nonsense substitutions and 2 frameshift insertions). 
Similar findings are reported in cBioPortal 
(http://www.cbioportal.org) among the 55,481 
cancer samples accessed, that show somatic 
mutations in BIRC5 occur in merely 0.2% of the 
tested samples (corresponding to 116 mutations, of 
which 65 are missense substitutions, 50 truncated 
genes or 1 other mutation). When mutations, 
amplifications, deep deletions and multiple 
alterations were considered, the total of cancer 
samples with any type of genetic alteration in BIRC5 
was 969 (1.7%). 
Implicated in 
Angiosarcoma 
In a cohort including 85 samples from angiosarcoma 
patients and 88 controls (54 hemangioma and 34 
pyogenic granuloma), nuclear BIRC5 expression 
was observed in all angiosarcoma patients, but in 
fewer than 7% of the control group. This data 
indicates that BIRC5 expression may be used as a 
diagnosis tool in angiosarcoma (Tsuneki et al., 
2017). In addition, genetic or pharmacological 
BIRC5 inhibition reduces cell proliferation in ISO-
HAS-B human angiosarcoma cells (Tsuneki et al., 
2017). 
Brain cancer 
Western blot analysis revealed that BIRC5 was 
expressed in 60.3% of glioma samples, which was 
associated with a reduced apoptosis ratio and high-
grade tumors (Bae et al., 2017). In agreement, 
samples obtained from gliosarcoma patients 
presented elevated expression of BIRC5 in the 
nucleus of tumor cells collected from brain lesions, 
when compared to normal brain cells (Chen et al., 
2010).  
BIRC5 expression was also associated to 
radioresistance: ionization of glioblastoma cell lines 
promoted BIRC5 upregulation, which mediated 
dedifferentiation to a stem-like phenotype and, 
consequently, induced a radioresistant phenotype 
(Dahan et al., 2014).  
Treatment of glioma cells with the survivin inhibitor 
YM155 overcomes resistance to TRAIL-induced 
apoptosis, by downregulating MCL1 and BIRC5 
(Premkumar et al., 2013). In glioblastoma cell lines, 
YM155 treatment reduced BIRC5 expression, and 
induced apoptosis and DNA fragmentation (Lai et 
al., 2012). Similar results were reported by Jane and 
colleagues (Jane et al., 2013), where YM155 
downregulated BIRC5 and MCL1 expression and 
inhibited cell growth in malignant human glioma 
cells. Interestingly, in resistant glioma cell lines 
attributed to EGFR activation, YM155 alone did not 
present any significant effects, however in 
combination with ABT-373, a BH3-only mimetic 
that targets the prosurvival members of the BCL2 
family, a synergic effect mediated by caspase 
activation was observed (Jane et al., 2013). 
Depletion of BIRC5 levels mediated by parthenolide 
treatment induced apoptosis and cell cycle arrest in 
glioblastoma cell lines (Tang et al., 2015). 
Cucurbitacin-I, another natural product, induced cell 
death in malignant glioma cells, while promoting 
G2/M accumulation, depletion of p-STAT3, p-
STAT5, p-JAK1 and p- JAK2 levels, and 
downregulation of AURKA, AURKB and BIRC5 
(Premkumar et al., 2015). Medulloblastoma also 
presents elevated level of BIRC5 expression, as 
observed for other brain cancers. Similarly, 
antagonists of BIRC5 impaired proliferation and 
survival of both murine and human medulloblastoma 
cells (Brun et al., 2015). High BIRC5 expression was 
associated to advanced stages and sporadic tumors in 
patients aged greater than 12 months (Islam et al., 
2000), which negatively impacted clinical outcomes 
(Azuhata et al., 2001). In addition, BIRC5/p53 and 
BIRC5/FAS ratios have been implicated in 
neuroblastoma prognosis (Sandler et al., 2002; Tajiri 
et al., 2001). In neuroblastoma and 
oligodendroglioma cell lines, BIRC5 silencing 
reduced cell viability while further inducing mitotic 
catastrophe and cell death by caspase-dependent and 
-independent pathways (Shankar et al., 2001). 
Breast cancer 
BIRC5 protein expression was found in 78% of high-
grade and 21.4% of low-grade patients with ductal 
carcinoma in situ, indicating that BIRC5 expression 
is associated with an advanced stage phenotype in 
breast cancer (Chade et al., 2018). In addition, 
increased 
Estrogen positive breast cancer subtypes have been 
connected to increased BIRC5 regulation, w levels 
of BIRC5 mRNA (2.24 fold) were observed in whole 
blood samples from breast cancer patients when 
compared to healthy donors (Wang et al., 2016).  
Estrogen positive breast cancer subtypes have been 
connected to increased BIRC5 regulation, which was 
reverted by treatment with the natural compound 
myricetin, enhancing apoptosis (Jiao and Zhang, 
2016). In triple negative breast cancer, 
chemoresistance and metastasis were associated to 
elevated DEPTOR protein expression that, in turn, 
induced a higher expression of BIRC5, both in vitro 
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and in vivo (Parvani et al., 2015). Survivin and 
survivin-ΔEx3 were overexpressed and associated to 
chemoresistance in non-responder samples using ex 
vivo organotypic cultures of primary human breast 
tumors (Faversani et al., 2014). Using shRNA 
targeting BIRC5 splice variants isoforms, Zheng and 
colleagues (Zheng et al., 2011) demonstrated that 
apoptosis rates were improved considerably by 
survivin depletion, but survivin-ϚEx3 isoform 
silencing only moderately inhibited cell survival and 
growth in a breast cancer model.  
In breast cancer cells, combined therapy using 
panobinostat with gemcitabine markedly diminished 
BIRC5 expression (Budman et al., 2012). Similarly, 
SMAC mimetics (BV6, Birinapant) and BH3-
mimetics (ABT-737/263) combined with paclitaxel 
treatment demonstrated positive results regarding 
BIRC5 downregulation (Panayotopoulou et al., 
2017).  
Chemoresistance was also related to the extracellular 
LGALS1 (galectin-1) expression that, moreover, 
contributes to cancer progression and doxorubicin 
resistance in triple negative breast cancer. It must be 
stated, herein, that galectin-1 expression is mediated 
by STAT3 activation, which is a transcription factor 
that culminates in BIRC5 upregulation, 
corroborating the role of BIRC5 in chemoresistance 
in breast cancer cells (Nam et al., 2017). The 
function for STAT3 in BIRC5 upregulation in breast 
cancer cells was also confirmed by Wang and 
colleagues (Wang et al., 2015), who demonstrated 
that MIR204 inhibits STAT3 activation and BIRC5 
expression.  
BIRC5 also participates on the invasive phenotype 
by regulating the expression of the vascular 
endothelial growth factor-C ( VEGFC) at both 
protein and mRNA levels, which culminates in a 
raised metastasis rate in breast cancer (Cai et al., 
2012). In agreement, elevated BIRC5 expression 
was associated with poor prognostic in stage II/III 
breast cancer patients (Hamy et al., 2016). The 
authors proposed that BIRC5 expression might be 
theranostic, and suggest that high BIRC5-expressing 
breast cancer patients would be randomized to 
receive BIRC5 targeting drugs (Hamy et al., 2016). 
A recent study that evaluate the transcriptome of 
primary breast cancer patients, demonstrated that, 
along with NEK2 and TOP2A, BIRC5 gene was 
amplified in obese breast cancer patients, reinforcing 
that this gene may be druggable for this population 
(Nuncia-Cantarero et al., 2018). One factor that may 
explain such observation is the synthesis of visfatin, 
an adipokine secreted by adipocytes, macrophages 
and inflamed endothelial tissue, which was found to 
be increased in obese and breast cancer patients, 
while exerting a protective effect on BIRC5, raising 
its levels and, thus, contributing to tumor 
progression (Gholinejad et al., 2017).  
In breast cancer cell lines, including triple negative 
phenotype and tamoxifen-resistant cells, YM155, a 
BIRC5 inhibitor, as previously mentioned, reduces 
cell viability, with IC50 values in the low nanomolar 
range, and induced autophagy (Cheng et al., 2015).  
In breast cancer cell lines, ABT-263 (navitoclax), a 
BCL2 family protein inhibitor, promoted a negative 
modulation of BIRC5 levels in MDA-MB-231, but 
not in MCF-7, which was associated with a higher 
sensitivity to the drug (Lee et al., 2018). 
Cervical carcinoma 
In a recent meta-analysis including eleven studies 
and a total of 865 cervical carcinoma patients, Cheng 
and colleagues (Cheng et al., 2016) reported that 
elevated BIRC5 expression was positively 
associated with aggressive clinicopathological 
features, lymph node metastasis and poor survival 
outcomes. 
Colorectal cancer 
Immunohistochemical analysis evidenced that 
patients with colorectal adenocarcinomas exhibited 
higher BIRC5 levels compared to adjacent non-
tumor colorectal mucosa. In the same study, the 
authors demonstrated that BIRC5 silencing, by 
siRNA, suppressed survival and cell invasion, and 
induced cell cycle G0/G1 arrest and apoptosis in 
colorectal cancer cells (Wang et al., 2017b). BIRC5 
splice variants were also evaluated in colorectal 
cancer, and the distribution of mRNA observed was 
the following: 48% of wild-type survivin, 38% of 
survivin-2B isoform and 29% of survivin-ΔEx3 
isoform. The mRNA expression of wild-survivin and 
survivin-ΔEx3 was related with tumor size and 
invasion, respectively (Pavlidou et al., 2011). In 
contrast, BIRC5 levels were not associated with 
patients with advanced colorectal adenoma (Choi et 
al., 2017).  
Elevated expression of BIRC5 was also correlated 
with levels of CD133+, which is associated to 
chemoresistance to 5-fluorouracil, in colon cancer 
cells. The elevated expression of BIRC5 induced by 
activation of the CXCL12/ CXCR4 signaling 
pathway in cells exposed to radiation may be a 
crucial factor for the acquisition of chemoresistance 
in this cancer type (Wang et al., 2017a). However, 
no association was found between expression of 
BIRC5 and invasion, lymph node metastasis, nor 
histologic differentiation (Li et al., 2017). Survivin 
depletion by the EpCAM-aptamer-guided BIRC5 
RNAi enhanced colorectal cancer stem cells 
sensitivity to 5-FU and oxaliplatin, further inducing 
apoptosis, reducing tumor growth and improving the 
overall survival in a colorectal cancer xenograft 
model (AlShamaileh et al., 2017).  
The use of natural products was also implicated in 
reduction of BIRC5 levels, such as tanshinone I, an 
active compound from traditional Chinese herbal 
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medicine (Lu et al., 2016), and the Pinus roxburghii 
essential oil (Sajid et al., 2018). Additionally, 
treatment with tamoxifen β-estradiol or a 
combination of these two agents promoted decreased 
BIRC5 levels and impaired cell migration in 
colorectal cancer cells (Ou et al., 2017). In colon 
cancer cells, dimethoxy curcumin inhibited cell 
growth, increased apoptosis, reduced cell migration, 
downregulated BIRC5 expression and enhanced 
CDH1 (E-cadherin) in vitro and in vivo (Chen et al., 
2016).  
Treatment failure in colorectal cancer was 
previously associated to the presence of stem cells 
bearing a KRAS mutation, which, then, become 
resistant to chemotherapy. Treatment with Omega-3 
fatty acid DHA promoted a reduction of cell 
viability, with caspase-3 activation mediated by a 
decrease in transcript and protein levels of BIRC5 
and, moreover, an increase in MIR16-1 expression 
levels, suggesting that BIRC5 and microRNA-16-1 
to be promising molecular targets of DHA (Sam et 
al., 2018). 
Endometrial cancer 
In endometrial cancer, BIRC5 was identified to be 
critical for NEF2-driven progestin resistance. The 
authors also demonstrated that BIRC5 silencing 
enabled restoration of progestin sensitivity in NRF2-
overexpressing RL-95-2 cells (Fan et al., 2017). 
Gastric cancer 
Gastric adenocarcinoma patients undergoing 
gastrectomy were evaluated for the expression of 
markers with relevance for tumor progression and 
prognosis. Among them, 93.9 % of samples from 
gastric cancer patients presented nuclear sub-
localization of BIRC5, which was associated with a 
poor prognosis (Lins et al., 2016). It has been 
demonstrated that BIRC5 upregulation increased 
VEGF expression in gastric cancer (Zhang et al., 
2014). The authors also demonstrated that 51.3% of 
gastric carcinoma samples presented BIRC5 
expression, which was located mainly in the 
cytoplasm of tumor cells, associated with lymph 
node metastasis and reduction of overall survival in 
the univariate analysis (Zhang et al., 2014).  
BIRC5 knockdown using shRNA promoted an 
elevated sensitivity to radiation and chemotherapy 
using 5-FU, demonstrating that the modulation of 
BIRC5 levels may be an important adjuvant therapy 
for gastric cancer patients (Shen et al., 2012). In 
agreement, BIRC5 silencing mediated by siRNA 
increased apoptosis rates, inhibited cell proliferation 
in a cisplatin-resistant cell line (Li et al., 2014) and 
impaired cell migration in gastric cancer cells (Li et 
al., 2015). 
Head and neck squamous cell 
carcinoma 
Hih levels of BIRC5 was observed in samples from 
head and neck squamous cell carcinoma patients, 
which was associated with poor survival outcomes 
and chemotherapy resistance (Zhang et al., 2015a) In 
head and neck squamous cell carcinoma cells, a 
treatment targeting BIRC5 by using YM155 
increased apoptotic and autophagic cell deaths, 
suppressing pro-survival pathways (Zhang et al., 
2015a).  
Similarly, treatment with an aliphatic hydroxamate-
based compound targeting BIRC5 reduced survivin 
levels through LKB1/AMPK/p38MAPK signaling, 
and further enhanced p63 phosphorylation and p21 
activation (Yen et al., 2018). 
Hepatocellular carcinoma 
In SMMC-7721 hepatocellular carcinoma cells, 
treatment with berbamine, a natural compound from 
Chinese medicine, promoted upregulation of p53 
expression and downregulation of BIRC5, which 
further triggered mitochondria signaling pathway-
mediated apoptosis (Cao et al., 2018). 
Kidney cancer 
In renal cell carcinoma patients, high BIRC5 
expression was associated with increased TNM stage 
and high Fuhrman grade, which indicates that 
BIRC5 may be a good prognosis predictor (Ma et al., 
2017).  
Furthermore, BIRC5 has been associated with tumor 
progression and chemoresistance to temsirolimus, an 
MTOR inhibitor. Strategies that abrogate survivin 
expression, such as shRNA-mediated BIRC5 
silencing or pharmacological approach (YM155), 
reduced chemoresistance of renal cell carcinoma 
cells in vitro and in vivo (Carew et al., 2015).  
Other signaling pathways seem to converge to the 
induction of BIRC5 expression in renal cell 
carcinoma.  
For instance, combined treatment between the 
histone deacetylase (HDAC) inhibitor OBP-801 and 
the phosphatidylinositol 3-kinase (PI3K) inhibitor 
LY294002 synergistically inhibited cell growth and 
induced apoptosis in renal cell carcinoma through 
BIRC5 downregulation (Yamada et al., 2013). 
Leukemia 
In chronic myeloid leukemia, the oncogenic 
signaling induced byBCR/ ABL1 leads to BIRC5 
upregulation by activating the JAK2/STAT3 
pathway.  
 
Moreover, BIRC5 silencing promoted pronounced 
cytotoxic effect in both imatinib-sensitive and -
resistant chronic myeloid leukemia cell lines, a 
similar effect to that observed after treatment with 
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shepherdin, a cell-permeable peptidomimetic 
compound that downregulates BIRC5. These 
findings indicate that survivin may be a target in 
BIRC5-overexpressing leukemias (Stella et al., 
2013). The combined use of C82 (a Wnt/β-catenin 
signaling modulator) and nilotinib in chronic 
myeloid leukemia progenitor cells inhibited the 
expression of CD44, MYC, BIRC5, p-CRKL and p-
STAT5 (Zhou et al., 2017)  
In acute myeloid leukemia, BIRC5 overexpression is 
involved in drug resistance of leukemia stem cells, 
regulated by the ERK/MSK/Sp1/MYC axis (Zhang 
et al., 2015b). Interestingly, BIRC5 depletion, by 
siRNA, reduced cell proliferation, induced 
apoptosis, and synergistically enhanced cytotoxicity 
of etoposide in acute myeloid leukemia cells 
(Karami et al., 2013). Other molecular signaling that 
has been involved in acute myeloid leukemia 
resistance is the expression of MUC1 (MUC1-C), an 
oncoprotein critical for the onset of tumorigenesis, 
which is overexpressed in acute myeloid leukemia 
blasts and leukemia stem cells. It has been 
demonstrated that targeting MUC1-C reduced 
BIRC5 levels and increased sensitivity to cytarabine, 
indicating that BIRC5 is involved in multiple 
signaling pathways required for survival in leukemia 
cells (Stroopinsky et al., 2018).  
Acute lymphoblastic leukemia (ALL) patients also 
presented elevated levels of BIRC5 and VEGF, 
especially prior to treatment with an association of 
idarubicin, cytosine arabinoside and etoposide. 
Nevertheless, those levels decreased after treatment 
(Yang et al., 2013). In children diagnosed with acute 
lymphoblastic leukemia, BIRC5 expression was 
higher compared to healthy donors. The same group 
of patients was monitored during the entire treatment 
period and those who went in to complete remission 
of the disease presented decreased levels of BIRC5, 
compared to diagnosis sample. In contrast, BIRC5 
protein levels were elevated in non-survived ALL 
patients (Yahya et al., 2012). In acute lymphoblastic 
leukemia primary samples and cell lines, treatment 
with YM155 exhibited elevated cytotoxicity by 
induction of DNA damage, leading to 
phosphorylation of CHEK2 and H2AFX and 
promoting suppression of BIRC5 expression (Chang 
et al., 2015). 
It is well accepted that leukemia stem cells 
contribute to a reduced treatment efficacy and also to 
chemoresistance. The natural product curcumin 
decreased BIRC5 levels in leukemia stem cell-like 
KG1a in a combined treatment with busulfan, which 
may overcome such chemoresistant of leukemia 
stem cells (Weng et al., 2015).  
Furthermore, Li and colleagues (Li et al., 2018) 
observed an association between the presence of C 
allele of BIRC5 polymorphism rs9904341, but not of 
rs8073069, and an increased risk of acute leukemia 
development in a cohort including 182 childhood 
acute leukemia patients and 200 controls. 
Liver cancer 
In samples from hepatocarcinoma patients, 55.4% of 
tumor tissues were positive for BIRC5 expression, 
which was higher when compared to non-tumor 
adjacent tissues (2%). Additionally, BIRC5 
expression has been directly correlated with 
unfavorable clinical staging and tumor score, and the 
presence of extrahepatic metastasis. The authors also 
demonstrated a positive correlation between BIRC5 
and VEGF expression, implying that besides 
avoiding apoptosis, BIRC5 may induces 
angiogenesis contribute to tumor dissemination 
(Tian et al., 2018). 
Lung cancer 
A meta-analysis study including 3,206 non-small 
cells lung cancer (NSCLC) patients and 816 normal 
controls, BIRC5 was found to be overexpressed in 
tumor samples and strongly correlated with 
histological differentiation, tumor-node-metastasis 
stage and lymph node metastasis, which indicates 
that BIRC5 may be a tumor progression marker for 
such cancer type (Duan et al., 2016). Another study 
indicated that BIRC5 may be involved in 
chemoresistance of NSCLC cells (Hu et al., 2016). 
Additionally, it was demonstrated that the GC+CC 
genotypes in the promoter region (-31) of the BIRC5 
gene (polymorphism rs9904341) were significantly 
associated with EGFR mutations in a cohort of 360 
lung cancer patients (Liu et al., 2016).  
Recently, BIRC5 was identified as a target of 
MIR195, a microRNA that induced apoptosis and 
senescence in NSCLC cells (Yu et al., 2018). A 
combined therapy using the natural product 
resveratrol and the epidermal growth factor receptor 
(EGFR) inhibitor erlotinib promoted an increase in 
cell death mediated by BIRC5 depletion in NSCLC 
cells (Nie et al., 2015). Similarly, depletion of 
BIRC5 induced by treatment with YM155 increased 
the sensitivity of such cells to radiation (Hu et al., 
2015).  
Treatment with the natural product fisetin also 
increased sensitivity to cisplatin in cisplatin-resistant 
NSCLC cells by modulation of 
MAPK/BIRC5/Caspase axis (Zhuo et al., 2015).  
Lung cancer stem cells were more sensitive to 
FL118, a BIRC5 inhibitor, than cisplatin. 
Additionally, FL118 downregulated cancer stem cell 
related markers, which may improve drug-sensitivity 
in this kind of tumor cells (Wang et al., 2017c). 
Lymphoma 
In non-Hodgkin lymphoma, specifically the 
aggressive subtype extranodal natural killer/T-cell 
lymphoma, which is frequently associated with 
resistance to anthracyclines, presence of BIRC5 
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serum levels were detected in approximately 25% of 
patients, which is associated with advanced stages of 
the disease. In addition, the percentage of lymphoma 
cells that demonstrated BIRC5 nuclear localization 
was significantly associated with BIRC5 serum 
concentration (Kim et al., 2015).  
BIRC5 expression was positive in 40% of lymph 
node biopsy of diffuse large B-cell lymphoma 
patients. Such observation correlated with 
unfavorable factors for therapy response and 
predicted shorter survival outcomes (Markovic et al., 
2012). A meta-analysis, including 17 studies and 
1,352 diffuse large B-cell lymphoma patients, found 
positive BIRC5 expression to be associated with 
advanced clinical stages and reduced overall survival 
(Zhang et al., 2015c).  
The combinatory use of bendamustine and rituximab 
associated with BIRC5 inhibitor, YM155, presented 
potentiating effects on induction of cell death by 
triggering DNA damage and cell cycle arrest in 
lymphoma cells, and, moreover, reduced tumor size 
and metastatic capacity in diffuse large B-cell 
lymphoma xenograft murine models (Kaneko et al., 
2014). A combined treatment of rituximab and 
YM155 was shown to reduce tumor growth more 
effectively than monotherapy (Kita et al., 2012). In 
B and T cell lymphoma cells, BIRC5 abrogation 
using the non-toxic tellurium compound, AS101, has 
overcome chemoresistance, sensitizing these cells to 
paclitaxel (Danoch et al., 2015). BIRC5 expression 
presented anti-apoptotic functions and is regulated 
by NF-κB and PI3K/AKT signaling pathways in 
nasal NK/T-cell lymphoma cells (Sun et al., 2015). 
Malignant pleural mesothelioma 
In two independent cohorts of malignant pleural 
mesothelioma patients, nuclear BIRC5 expression in 
both, pre- and post-chemotherapy tissues, was 
associated with shorter freedom from recurrence and 
overall survival, indicating that BIRC5 expression 
may be a prognostic factor for poor clinical 
outcomes in this cancer type (Meerang et al., 2016). 
Melanoma 
BIRC5 expression was previously demonstrated in 
melanoma and melanocytic nevus, which 
demonstrated all nevi, regardless of histologic type, 
expressed detectable levels of BIRC5 (Yan et al., 
2006). Additionally, a cytoplasmic staining of 
BIRC5 was evidenced in dysplastic nevi (Florell et 
al., 2005). In normal melanocytes, it was 
demonstrated that p53 and RB1 are required to 
repress BIRC5 expression. A role for E2F2 in the 
negative regulation of BIRC5 expression was also 
pointed out (Raj et al., 2008). Increased BIRC5 
expression was observed in vivo in melanocytes that 
were more resistant to UV-induced apoptosis, which 
was further associated to lower rates of spontaneous 
apoptosis, earlier melanocytic tumor development 
and increased tendency for lymph node and lung 
metastasis (Thomas et al., 2007). Furthermore, 
BIRC5 overexpression in melanocytes activated the 
AKT and MAPK signaling pathways, acquiring a 
more invasive phenotype, and demonstrating the 
involvement of BIRC5 on the onset and progression 
of melanoma (McKenzie et al., 2013).  
In melanoma cells, BIRC5 was associated to 
enhanced AKT and MAPK signaling dependent 
migration and invasion, as well as to the 
upregulation of ITGA5 (α5 integrin) (McKenzie et 
al., 2010). BIRC5 silencing through RNA 
interference promoted cell cycle arrest and reduced 
cell proliferation and metastasis in vivo and in vitro 
in melanoma models. Moreover, as observed for 
other tumor types, BIRC5 inhibition led to increased 
sensitivity to chemotherapy in melanoma cells 
(Kedinger et al., 2013). In another study, a proposed 
strategy to overcome chemoresistance and to 
promote melanoma cell death was the combination 
of vemurafenib and Nutlin-3, whose synergism was 
responsible for BIRC5 depletion and apoptosis 
induction (Ji et al., 2013).  
Pharmacological suppression of BIRC5 expression, 
using YM155, increased apoptosis induction and 
tumor regression in melanoma xenograft models. In 
the same study, combined treatment of YM155 and 
docetaxel presented potentiating effects in induction 
of apoptosis compared to monotherapy, 
corroborating the notion that targeting BIRC5 may 
be an interesting approach in melanoma 
management (Yamanaka et al., 2011). Similar 
results were obtained using natural compounds 
extracted from plants that target BIRC5 through β-
catenin and STAT3 suppression (Habibie et al., 
2014).  
Another alternative approach for targeting BIRC5 
was the generation of recombinant fusion proteins 
containing the TAT protein transduction domain and 
either wild-type survivin (TAT-Surv-WT) or a 
dominant- negative mutant (TAT-Surv-T34A). The 
mutant promoted in vitro cell death through 
apoptosis and DNA fragmentation in melanoma 
cells. In vivo injections of such mutant in melanoma 
xenograft mice increased apoptosis, induced 
aberrant nuclei formation and impaired tumor 
growth (Yan et al., 2006).  
BIRC5 mRNA was detected in 98% of samples from 
metastatic melanoma patients. High BIRC5 mRNA 
levels were significantly associated with poor overall 
survival (Takeuchi et al., 2005). 
Multiple myeloma 
BIRC5 expression was positive in 35% of samples 
from newly diagnosed multiple myeloma patients, 
but no association with clinical and laboratorial 
characteristics, treatment response and survival 
outcomes was found (Zeng et al., 2014). On the other 
hand, Yang and colleagues (Yang et al., 2016b), in a 
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study that evaluated the efficacy of a combination 
treatment with fludarabine, vincristine, epirubicin, 
dexamethasone and thalidomide (FVADT) 
chemotherapy regimen for refractory multiple 
myeloma patients, reported that complete remission 
and efficacy rates were significantly lower in the 
BIRC5-positive group, when compared with the 
BIRC5-negative group. 
Myxoid liposarcoma 
Using high-throughput drug screen and myxoid 
liposarcoma cell lines, BIRC5 has been identified as 
a relevant protein important for cell survival (de 
Graaff et al., 2017). 
Oral squamous cell carcinoma 
Elevated BIRC5 mRNA expression was observed in 
samples from oral squamous cell carcinoma patients 
compared to peritumoral or normal tissues (Li et al., 
2012). Still, such increase was shown to be 
insufficient to drive tumor progression in oral 
squamous cell carcinoma, however nuclear 
expression of BIRC5 was correlated with tumor 
stage and differentiation grade (Liu et al., 2017). 
Additionally, the authors suggested that nuclear 
localization of BIRC5 has been due to the acetylation 
at K129 in the protein C-terminal region (Liu et al., 
2017). In oral squamous cell carcinoma cells, 
treatment with YM155 reduced BIRC5 levels and 
increased apoptosis rates (Yan and Su, 2017). 
Ovarian cancer 
High BIRC5 levels correlate with advanced stage, 
metastasis and poor disease-free survival in ovarian 
cancer (Aune et al., 2011; No et al., 2011). 
Moreover, BIRC5 serum levels were significantly 
higher, while DIABLO (Smac) levels were 
significantly lower in patients with serous ovarian 
carcinoma when compared to healthy controls 
(Dobrzycka et al., 2015).  
The association of nuclear and cytoplasmic BIRC5 
expression and prognosis remains controversial in 
ovarian cancer. The evaluation of BIRC5 expression 
in patients treated with taxane and platinum agents 
concluded that, in this treatment regimen, higher 
nuclear BIRC5 expression was associated with 
reduced risk of disease recurrence and death 
(Felisiak-Golabek et al., 2011). By contrast, another 
study reported that nuclear BIRC5 was significantly 
associated with chemoresistance to taxane-based 
chemotherapy, predicting poor progression-free 
survival (Du et al., 2015). Immunohistochemistry 
analysis revealed that BIRC5 expression presented a 
positive correlation with FIGO stage in epithelial 
ovarian cancer, benign epithelial ovarian tumor 
tissue and borderline ovarian tumor tissues (Ju et al., 
2016).  
BIRC5 splices variants were also correlated to the 
development of ovarian cancer and resistance to 
chemotherapy. Taxane-resistant ovarian cancer cells 
expressed higher BIRC5 mRNA levels than their 
taxane-sensitive counterparts. Survivin-2B 
expression was significantly higher in taxane-
resistant cells, when compared to sensitive cells 
(Vivas-Mejia et al., 2011).  
YM155 treatment induced BIRC5 downregulation, 
cell growth inhibition, cell cycle arrest, reactive 
oxygen species formation and apoptosis, and 
enhanced docetaxel efficacy in ovarian cancer cell 
lines (Hou et al., 2018). In agreement, in ovarian 
cancer cells, BIRC5 knockdown enhanced cisplatin 
sensitivity in resistant cancer cells, inducing 
apoptosis and inhibiting the invasive process through 
downregulation of MMP2 (Jiang et al., 2013). 
Pancreatic cancer 
In a cohort of 51 pancreatic adenocarcinoma 
patients, BIRC5 expression was found in 49% of 
samples and was associated with poor survival 
outcomes (Contis et al., 2018). Similar results were 
reported by Zhou and colleagues (Zhou et al., 2018), 
who described that nuclear BIRC5 was higher in 
tumor compared to non-tumor pancreatic tissues, 
and a high nuclear BIRC5 expression was an 
independent predictor of disease-specific survival in 
ductal pancreatic adenocarcinoma patients. In 
pancreatic cancer models, FL118, a BIRC5 inhibitor, 
reduced cell viability, including for stem cell like and 
cisplatin-resistant cells, and decreased xenograft 
tumor growth and metastasis (Ling et al., 2018). 
Prostate cancer 
BIRC5 levels was not detected in normal tissues, 
slightly detected in benign prostate hyperplasia 
tissues and considerably higher in prostate 
adenocarcinoma, which was positively correlated 
with higher tumor stage (Eslami et al., 2016). In 
agreement, increased BIRC5 levels were also 
associated with poor survival outcomes in prostate 
cancer patients (Xu et al., 2015).  
In a cohort including 157 prostate cancer patients 
and 145 controls, genetic polymorphisms c.-31G>C 
(rs9904341), c.454G>A (rs2071214), and c. 
*148T>C (rs1042489) of BIRC5 were associated 
with risk for prostate cancer development (Karimian 
et al., 2018).  
Treatment with BIRC5 inhibitor (YM155) inhibited 
cell growth, cell migration and invasion in prostate 
cancer cells (Xu et al., 2015). Overexpression of 
miR-494 (a microRNA targeting BIRC5) and/or 
BIRC5 silencing using shRNA attenuated cell 
growth in vitro and in vivo (Zhu et al., 2016). 
Moreover, treatment of prostate cancer cells with a 
selective inhibitor of nuclear export, KPT-330, 
inhibited proliferation and promoted apoptosis of 
tumor cells, by increasing protein degradation of 
exportin XPO1, BIRC5 and CCND1, further leading 
to cell cycle arrest and apoptosis (Gravina et al., 
2015). Natural products, such as the triterpenoid 
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pristimerin, demonstrated that BIRC5 levels may 
modulate therapeutic responses, once BIRC5-
overexpressing prostate cancer cells became 
resistant to pristimerin (Liu et al., 2014). 
Salivary adenoid cystic carcinoma 
In SACC-83 salivary adenoid cystic carcinoma cells, 
treatment with simvastatin reduced cell viability and 
induced apoptosis by decreasing BIRC5 levels (Cai 
et al., 2018). 
Thyroid cancer 
Nicotinamide phosphorybosiltransferase (NAMPT), 
a marker for thyroid cancer that is positively 
associated with tumor stage and metastasis, 
presented a positive correlation with BIRC5 
(survivin) and survivin splice variant º, but not with 
survivin-2B, expressions, reinforcing that survivin 
and its variant ΔEx3 are associated with poor 
prognosis and advanced stage cancer (Sawicka-
Gutaj et al., 2015). 
Urinary tract cancer 
In SK-NEP-1 Wilms tumor cells, YM155 treatment 
reduced cell proliferation, induced apoptosis and 
inhibited growth of xenograft tumors. Interestingly, 
YM155 treatment promoted an elevation in levels of 
other BIRC-related genes, such as BIRC3 and 
BIRC8, suggesting that the regulation of cell death 
induced by BIRC5 suppression is highly 
orchestrated with other members of the IAP family 
(Tao et al., 2012). 
To be noted 
Pharmacological Advances for BIRC5 inhibition 
YM155, a small-molecule BIRC5 inhibitor, was 
developed in 2007 and tested in multiple cancer 
models. YM155 caused a concentration-dependent 
cytotoxic effect with IC50 values reaching nanomolar 
concentrations (Nakahara et al., 2007; Rauch et al., 
2014). The mechanism of action for YM155 
involves a selective inhibition of BIRC5 promoter 
activity by disrupting Sp1 interaction in a specific 
region of the BIRC5 core promoter. Such repression 
occurs in a cell cycle-independent manner (Cheng et 
al., 2012).  
A novel survivin inhibitor developed in 2012, 
FL118, presents structural similarities to irinotecan.  
Such molecule selectively inhibits survivin promoter 
activity and gene expression in a TP53 status-
independent manner.  
Additionally, it promotes the inhibition of three 
additional cancer-associated survival genes (MCL1, 
BIRC4 and BIRC3) (Ling et al., 2012). FL118 was 
able to suppress BIRC5 expression in cancer stem 
cells in a lung cancer model (Wang et al., 2017c), 
which are known to be a cell population that presents 
chemoresistance and are responsible for disease 
recurrence in multiple type of cancer (Zhao, 2016).  
Vaccines against BIRC5 
 Survivin-2B80-88 (AYACNTSTL) is an antigenic 
peptide that can be recognized by CD8+ cells and 
demonstrated promising results as a potent 
immunogenic cancer vaccine (Idenoue et al., 2005). 
By using an HLA-A24/survivin-2B80-88 tetramer, 
the number of cytotoxic T-lymphocytes precursors 
in peripheral blood mononuclear cells of HLA-A24+ 
cancer patients was increased. Interestingly, 
cytotoxic cells positive for this peptide were found 
among peripheral blood mononuclear cells obtained 
from 100% of patients with breast cancers (n=7), 
83% with colorectal cancers (n=7) and 57% with 
gastric cancers (n=7) (Idenoue et al., 2005).  
Dendritic cells vaccines using recombinant BIRC5 
were tested in hormone refractory prostate cancer 
patients and results revealed cellular response, 
disease stabilization, partial tumor remission and no 
adverse events (Xi et al., 2015).  
Using the DepoVax platform, a BIRC5 vaccine was 
developed (DPX-Survivac) and produced antigen-
specific immune responses in ovarian cancer 
patients. Of note, 12 out of 18 ovarian patients 
remained without clinical progression after a 6-
month treatment (Berinstein et al., 2015).  
A study using vaccination with a long BIRC5 
peptide demonstrated a BIRC5-specific CD8-
mediated tumor cell lysis and, more importantly, the 
presence of circulating anti-BIRC5 antibodies was 
found in both, murine glioblastoma models and 
human glioblastoma patients following vaccination. 
The same vaccine showed promising results in 
GL261 glioma and B16 melanoma murine models 
(Fenstermaker et al., 2018).  
Gene Therapy targeting BIRC5 
 Gene therapy has already been used as an approach 
for inhibiting the expression of BIRC5 and to 
improve cell death induction in cancer. A combined 
gene therapy using BIRC5 siRNA and the fusion 
suicide gene yCDglyTK system displayed a relevant 
antitumor effect, inducing apoptosis more efficiently 
and eradicating colon cancer cells. Furthermore, this 
therapeutic system was able to inhibit the migration 




Drug Clade Cancer type References 
YM155 Small-molecule survivin inhibitor 
Multiple cancer 
types 
Cheng et al., 2014; Jane 
et al., 2013; Kita et al., 
2012; Lai et al., 2012 
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FL118 Small-molecule survivin inhibitor Cancer Stem Cell Wang et al., 2017 
Vaccines 
Vaccine Clade Cancer Type References 




Idonoue et al., 2005 
Dendritic Cell 
Vaccines 





Xi et al., 2015 
DPX-Survivac 
BIRC 5 vaccine developed based on 
DepoVax platform 
Ovarian cancer Berinstein et al., 2015 
SurVaxM Long BIRC5 peptide Gliobastoma 
Fernstermarker et al., 
2018 
Gene Therapy 
Strategy Cancer Type References 
Suicide gene yCDglyTK combined with BIRC5 siRNA Colon cancer cells Ye et al., 2017 
Heparin-polyethyleneimine (HPEI) nanoparticles to deliver a 
dominant-negative human BIRC5 T34A (hs-T34A) 
Ovarian carcinoma Luo et al.,2016 
Packaging RNA (pRNA) of bacteriophage phi29 DNA-
packaging motor to carry BIRC 5 and methallotionein siRNA 
Ovarian carcinoma Tarapore et al., 2011 
Adeno-associated virus (aaV)-mediated the dominant-negative 
human BIRC5 T34A (raaV-Sur- Mut(T34a) 
Gastric cancer Dang et al., 2015 
Nanotechnology 
Strategy of use Nanoparticle Cancer Type References 
Nanoparticles for 
siRNA delivery 
Fe3O4 core covered respectively by 
polyacrylate (PA) and polyethyleneimine 
(PEI) layer (Fe3O4-PA-PEI) 
Breast cancer Arami et al., 2016 
Magnetic nanoparticles containing 
polyethyleneglycol-lactate polymer (PEG-
LAC), chitosan, and polyethyleneimine 
(PEI) 
Breast cancer and 
Leukemia 
Arami et al., 2017 




Sun et al., 2016 









Nanoparticles were also developed for co-




Jin et al., 2018; Salzano 
et al., 2015 
 
Table 2. Summary of BIRC5 targeting strategies in cancer. 
 
Gene therapy using degradable heparin-
polyethyleneimine (HPEI) nanoparticles to deliver a 
dominant-negative human BIRC5 T34A (hs-T34A) 
gene was also used in ovarian cancer with promising 
results. HPEI nanoparticles effectively delivered the 
hs-T34A into ovarian carcinoma cells with low 
systemic cytotoxicity. Additionally, intraperitoneal 
administration of HPEI/hs-T34A complexes 
inhibited tumor growth in ovarian cancer xenograft 
murine model (Luo et al., 2016). The use of 
packaging RNA (pRNA) of bacteriophage phi29 
DNA-packaging motor to carry siRNA for combined 
BIRC5 and metallothionein silencing presented a 
stronger effect on reducing cell proliferation and 
aggressiveness in ovarian tumor cell lines than either 
one applied alone (Tarapore et al., 2011).  
Adeno-associated virus (aaV)-mediated the 
dominant-negative human BIRC5 T34A (raaV-Sur-
Mut(T34a)) delivery inhibited cell proliferation, 
induced apoptosis and sensitized gastric cancer cells 
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to 5-FU in vitro and impaired tumor growth in vivo 
(Dang et al., 2015).  
Nanotechonology for BIRC5 depletion  
 Several nanotechnology-based systems were 
developed to improve the delivery of siRNA or 
shRNA targeting BIRC5 in cancer cells, including a 
Fe3O4 core covered respectively by a polyacrylate 
(PA) or polyethyleneimine (PEI) layer (Fe3O4-PA-
PEI) (Arami et al., 2016). Moreover, magnetic 
nanoparticles containing polyethyleneglycol-lactate 
polymer (PEG-LAC) have also been used for such 
means, as well as other systems, like chitosan and 
polyethyleneimine (PEI) (Arami et al., 2017), 
poly(ethylene glycol)-modified chitosan (PEG-CS) 
(Sun et al., 2016), NDCONH(CH2) 2NH-
VDGR/survivin (Bi et al., 2016) and 
monomethoxypolyethylene glycol-chitosan (mPEG-
CS) (Yang et al., 2016a). These systems have been 
shown to inhibit expression of BIRC5, increase 
apoptosis, reduce cell proliferation and metastasis, 
and to shrink tumor size in multiple cancer models. 
Nanoparticles were also developed for co-delivery of 
siRNA targeting BIRC5 and paclitaxel, which 
constrained tumor growth, prolonged survival and 
augmented anticancer properties of paclitaxel in 
murine cancer models (Jin et al., 2018; Salzano et al., 
2015).  
A summary of approaches to BIRC5 targeting in 
cancer is described in Table 2. 
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